# Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

> **NCT02462525** · PHASE1 · TERMINATED · sponsor: **AbbVie** · enrollment: 74 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** ABBV-838
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02462525
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05-06
- **Primary completion:** 2017-12-06
- **Final completion:** 2017-12-06
- **Target enrollment:** 74 (ACTUAL)
- **Why stopped:** No Go decision for ABBV-838
- **Last updated:** 2018-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02462525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02462525, "Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02462525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*